The Kölner Dom, Wise Men Relics, and Pharma Social Media

The Cologne Cathedral (German: Kölner Dom) is a Roman Catholic cathedral in Cologne, Germany. It took over 600 years to complete the construction of this famous church.

The Dom is said to house the "relics" of the three wise men. According to wikipedia, "the relics of the Magi were taken from Milan by Holy Roman Emperor Fredrick Barbarossa and given to the Archbishop of Cologne, Rainald of Dassel in 1164. The Three Kings have since attracted a constant stream of pilgrims to Cologne," and this made Cologne a major Germany city.

Last week I visited Cologne on invitation from Dr. Frank Antwerpes, shown in the photo below standing next to his new "vineyard" on his farm somewhere about 30 minutes - Autobahn time - outside Cologne.

Dr. Antwerpes is the CEO of DocCheck, a publicly-held company that specializes in healthcare marketing, customer relationship management and eCommerce.

DocCheck comprises a health professional portal web site and a creative ad agency (antwerpes ag), which develops and implements communication strategies for new and traditional media with an emphasis on healthcare and business-to-business. For more about DocCheck, read "DocCheck: Das Portal" and listen to this podcast interview of Dr. Antwerpes: "Building the First Global Community of Doctors".

I first met Frank about 13 years ago at a Pharma Internet conference in Philadelphia. At that time, the "hot topic" was the fact that the World Wide Web (WWW) was surpassing Gopher as the Internet protocol of choice. I doubt if anyone today remembers Gopher.

Also at that time, the FDA held its first public hearing on the regulation of pharma use by the Internet. Many of us recalled THAT hearing because of FDA's NEW hearing on the Internet, which was held last November.

Anyway, Dr. Antwerpes invited me to speak to his agency's clients about social media*. While there, I joked that it may take as long for the pharmaceutical industry to "master" social media as it took Kölners to complete the Dom.

It was a bit frustrating to speak to European pharma people about social media because I knew that most of the interesting stuff that pharmaceutical companies can use social media for -- ie, to communicate with patients -- cannot be done in Europe. Therefore, it may be a cold day in hell before European companies can master the use of social media to communicate with European citizens. Or maybe it will be only 600 years! But first, they have to find some wise men relics. Hmm... maybe that's why I was invited to speak!

[ *Antwerpes paid my travel expenses plus a fee to speak to his clients.]

Can You Read This "Fair Balance" on Race With Insulin Twitter Page, or Is It Just Me Having Problems?

The "Race with Insulin" branded Twitter account is old news (listen to this podcast "Novo Nordisk's Race With Insulin Campaign: It's Not Just About Twitter").

Celebrity racecar driver and Levemir spokesperson Charlie Kimball is still posting interesting and informative tweets such as "Heading to bed. Just used my Levemir® FlexPen®. For Levemir® (insulin detemir [rDNA origin]) prescribing Info: http://tinyurl.com/28dp52d" and Novo Nordisk is making the rounds at industry conferences describing how they were able to do this while staying within FDA regulatory boundaries.

I am not going to complain about "sleazy spam tweets" and wonder what value such tweets are to patients. Instead, I'd like to point out how UNREADBALE the "fair balance" (safety) information is on the Race With Insulin Twitter page, which you can find here. I've reproduced that part of the page on the left. 

I challenge you to read this either using this image or viewing the original statement on the Race With Insulin Twitter page. It's impossible!


Novo Nordisk should realize that many people with diabetes are older and may have vision problems made worse by diabetes. For the sake of these patients, shouldn't Novo make this safety information more readable?


I also think the FDA should take an interest in this and issue Novo Nordisk a "warning letter" as it has done in other cases where fair balance information is not as prominent as benefit information.


To be fair, however, the Twitter page shows no "benefit" statements at all! It just mentions the medical condition and the brand name. Technically, therefore, while the safety information is required by the FDA, it's probably OK with the FDA that it is unreadable because there is no benefit statements to compare it with. What a dilemma!


This is a case where the pharma company should go beyond what is merely required by the regulators and provide a useful service to the patients who are using their products. What do you think?



Aged Female "Ka-Boomers" Shun Social Media, Favor Email

A recent "She Says" survey, conducted by Pink Tank, a division of GSW Worldwide specializing in women and health, and Meredith Research Solutions, has been cited to show that "women are highly cynical about pharmaceutical marketing efforts, with 56% of those surveyed believing that pharmaceutical marketing does more harm than good" (see "'Ka-Boomers' blow up more perceptions of pharma advertising").

That's nothing new to me and not the most important piece of information I got from this study, which you can find here.

The most important insight I received from this survey is that these women -- whose MEDIAN age is 53.1 years! -- shun social media and favor email for spreading interesting health news via the Internet (see chart below).

Click on the chart to enlarge.

Sorry if this chart is difficult to read, but the "pink tank" pdf survey summary is so muted with feminine colors that it is very difficult to read with my baby-boomer eyes! I had to darken the image in PhotoShop considerably to get even this barely readable version. I guess the report is not meant to be read by the half of the survey respondents who are over 53.1 years old!

Whatever! The point is that only 4% of these baby boomer women (MEDIAN age = 53.1 years) use social media to discuss and share interesting health information with their peers. Only 1% (a rounding error) use Twitter for that purpose. Meanwhile, 34% of these women use good old, antiquated Email!

As reported in MedAd Blog, "Based on the survey results, Ms. Goffe-Wagner [senior VP and brand manager for Pink Tank] says there are some tactics pharmaceutical companies should be following when evaluating their marketing. 'When the brand is all about itself, women feel, as one put it in the survey, that it's patient before pocketbook,' [sic? should this read 'pocketbook before patient'?] Ms. Goffe-Wagner says. 'That’s the lens they are looking at; they are looking at what you say, and what you do, to see whether they feel that you’re just all about growing sales of your brand, or whether you’re really about improving health and the lives of women."

Another tactic that pharmaceutical companies should be following is to use Email to reach these women rather than social media.

BTW, I would be interested in seeing how women in different age groups feel about the issues studied in this survey. For example, women between the ages of 18 and 44 years may be more likely to use social media and 46.6% of them are using at least one prescription drug according to the survey.

Is Pharma Blocking or Supporting iPad Use by Sales Reps?

"Has anyone had any luck getting the iPad to connect to J&J email system," asks an anonymous sales rep on the J&J IT board of CafePharma. "My iPhone connects perfectly and I believe that the iPad should work just the same way. However, even with exactly the same settings it isn't working for me..."

"I called helpdesk," said another poster, "he said iPads, Android, and a few other things are blocked at a device family level from activesynching. Didn't say why."

On the Eisai Pharmaceuticals discussion board, another anonymous poster said "I heard that we are getting new ipads for e-detailing. Great now we have 2 systems for inventory and 2 systems for account management. I better be able to dowload some games and it better have a decent battery. Prob nope on the last 2 requests."

In response was this post: "Who wants an Eisai neutered iPAD? You know they will block all downloads. No apps, movies, or music. Screw that!"

On the other hand, it seems that Genentech is providing iPads to its sales force: "iPads will be overnighted to the entire sales force next Tuesday," said an anonymous poster to the Genentech board on June 8, 2010.

According to Quang Pham, CEO, LathianHealth - an eDetailing company - iPads definitely have a place in the future of eDetailing. He was speaking at a MedAdNews webinar on sales force effectiveness today. Pham did mention, however, that many eDetailing programs currently use Adobe Flash, which is not supported by iPad. Yet the low price point for iPads is a great incentive for pharma to goose its eDetailing vendors to develop programs specifically for the iPad.

In the same webinar, David Kerr, SVP Business Development at PDI, Inc. (a company that provides outsourced sales and marketing services) wondered whether the iPad was robust enough to be thrown around in a sales rep's bag. I use the iPad Case (see photo) to protect my iPad and have taken it everywhere in my backpack without any worries.